Equities

Luxbright AB

Luxbright AB

Actions
  • Price (SEK)0.99
  • Today's Change-0.01 / -1.00%
  • Shares traded45.88k
  • 1 Year change+113.82%
  • Beta0.8288
Data delayed at least 15 minutes, as of Sep 20 2024 14:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Luxbright AB is a Sweden-based technology company with a focus on developing and commercializing a new generation of X-ray tubes. Through patented technology, the Company offers X-ray tubes, generators and future X-ray systems to international system suppliers to be able to improve and protect lives by enabling sharper X-ray images. Luxbright's products aim to solve the problems that have characterized the X-ray market for a long time: limited image resolution, excessive heat, complicated X-ray tube design and limited mobility of X-ray systems. The technology is offered in two primary market segments: industriell non-destructive testing (NDT) and sakerhetsindustrin. The Company offers X-ray tubes with microfocus that can contribute to higher image resolution than traditional X-ray tubes. In addition to that, the Company is at the beginning of expanding the product portfolio with X-ray tubes containing cold cathodes, which leads to X-ray systems with reduced energy consumpt

  • Revenue in SEK (TTM)4.20m
  • Net income in SEK-22.23m
  • Incorporated2012
  • Employees10.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Dignitana AB86.49m-25.27m80.14m29.00--8.19--0.9265-0.3268-0.32681.130.12151.742.7615.193,203,482.00-50.91-42.21-122.38-68.9169.5666.09-29.22-57.290.5202-9.970.609--17.9020.5922.52---15.31--
Codelab Capital AS-96.88bn-96.88bn83.13m29.00--0.5169----------0.4624-----------6.63---7.43--83.80---39.82----0.00---69.66-3.83119.43---12.19--
Kontigo Care AB29.65m1.75m83.32m10.0037.471.7215.712.810.06940.06941.111.510.6241--8.03--3.68-0.42145.03-0.619569.9366.315.89-0.5205--10.000.0569--1.8016.95-92.68--44.94--
SciBase Holding AB (publ)25.71m-59.24m86.50m27.00--1.64--3.36-0.4495-0.44950.18840.24090.2990.73284.04952,222.30-68.89-68.63-89.67-87.7770.0261.28-230.41-300.203.11-62.080.00--29.9327.50-28.75--5.15--
Clinical Laserthermia Systems AB15.20m-68.04m95.61m7.00--1.04--6.29-10.14-10.142.195.320.28711.204.24---130.42-123.49-460.49-312.95-249.68-1,084.16-454.45-1,625.030.9119-18.950.0116--31.9935.55-12.92--18.26--
Observe Medical ASA-96.88bn-96.88bn99.98m5.00--0.6584----------0.5635-----------32.60---49.80--32.83---256.250.193--0.3425--43.14204.81-18.82--32.69--
BBS-Bioactive Bone Substitutes Oyj0.00-39.51m102.13m----1.17-----0.2926-0.29260.000.26470.00-------32.71-25.12-38.23-28.54-----------28.790.482-------12.64------
Toleranzia AB0.00-5.41m102.87m11.00--0.6808-----0.026-0.0260.000.76680.00----0.00-3.89-7.45-4.05-7.78------------0.00------11.79--63.90--
ScandiDos AB61.35m-9.67m103.19m26.00--2.36--1.68-0.2092-0.20921.270.7660.81841.316.88---12.90-12.60-23.54-21.9350.3951.58-15.76-15.370.9476-6.360.00---1.824.36-60.62---19.29--
Redsense Medical AB (publ)23.77m-3.98m108.54m5.00--3.38--4.57-0.2871-0.28711.651.950.75247.584.184,754,400.00-12.58-18.66-14.51-20.9920.47-2.72-16.72-46.284.00-89.340.00--74.1128.9448.47---23.62--
Luxbright AB4.20m-22.23m112.69m10.00--3.79--26.81-0.24-0.240.04540.26410.104--4.14420,270.00-55.02-61.39-62.23-70.36-134.43-577.85-528.90-2,529.110.7743-4,539.470.0084--55.58---20.07------
Episurf Medical AB12.10m-84.60m113.80m26.00--0.9675--9.40-0.2429-0.24290.03470.18070.0839--6.21432,142.80-58.81-47.46-67.73-52.01-----700.83-1,019.296.11--0.0321--53.6219.78-22.64---0.4158--
Glycorex Transplantation AB (publ)31.03m-27.83m119.29m15.00--3.26--3.84-0.3768-0.37680.42010.51860.4120.83823.691,348,913.00-36.96-11.30-46.32-13.1782.9191.60-89.70-33.241.09-71.860.2084---17.04-2.15-254.06---0.5593--
Iconovo AB6.10m-39.03m119.71m29.00--0.9747--19.63-3.01-3.010.45267.710.0434--1.04210,251.40-27.76-25.43-31.28-28.24323.68134.57-640.15-215.16----0.0669---58.65-9.884.71--34.70--
BibbInstruments AB0.00-11.84m128.49m4.00--3.72-----0.4417-0.44170.001.180.00-------31.46-39.57-33.52-42.71--59.36---8,032.404.34--0.00------2.72---1.94--
Phase Holographic Imaging PHI AB9.12m-21.81m146.16m17.00------16.02-0.8819-0.88190.3689-0.02730.23730.65981.18---56.73-62.04-88.25-79.6471.0663.16-239.04-328.500.1916-5.611.04--6.1617.9612.98--21.19--
Data as of Sep 20 2024. Currency figures normalised to Luxbright AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
FCG Fonder ABas of 30 Aug 202416.73k0.02%
Data from 30 Aug 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.